Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040.
The strategy is connected to several pillars of Vision 2030, a strategic roadmap launched by the Kingdom of Saudi Arabia (KSA) in April 2016 to diversify the country's economy, reduce dependence on oil, and develop public service sectors – with a particular emphasis on life sciences, and the wellbeing of its citizens.
What is the national biotechnology strategy of Saudi Arabia, and what does it hope to achieve? Here are five key takeaways:
1. Realising Vision 2030 goals
The National Biotechnology Strategy is closely aligned with Saudi Arabia's Vision 2030, contributing directly to 11 strategic objectives and indirectly impacting 26 others. The strategy will play a pivotal role in achieving national development targets, including enhancing healthcare access, promoting environmental sustainability, boosting international investment and new economic opportunities.
2. Economic diversification
By prioritising biotechnology, Saudi Arabia aims to diversify its economy and reduce reliance on oil revenue. The strategy sets ambitious targets to contribute over US$34.6 billion to the non-oil GDP by 2040. This focus on economic growth positions the biotech sector as a cornerstone of Saudi Arabia's future prosperity.
3. Healthcare innovation
The strategy highlights the transformative potential of biotechnology in improving healthcare outcomes for KSA citizens. Through initiatives such as genomics research, vaccine development, and biosimilar production, the Kingdom seeks to reduce reliance on imported drugs, and increase access to innovation therapies, ultimately extending average life expectancy by five years by 2040. The strategy will also be an important driver in talent development for the region, creating 11,000 high-quality, innovative job opportunities by 2030, and 55,000 by 2040.
4. Biotech leadership
Saudi Arabia aims to establish itself as a leading hub for biotechnology in the MENA region by 2030 and a global player by 2040. The strategy emphasises collaboration with international partners to drive scientific advancements and foster multinational cooperation in research and development. This collaborative approach positions the KSA as a key player in shaping the future of biotechnology on a global scale.
5. A localised industry
The National Biotechnology Strategy represents a concerted effort by government bodies to structure and develop the domestic biotech industry. By providing essential enablers such as sustainable talent development, cutting-edge infrastructure, regulatory excellence, strategic funding, and a conducive geographical model, the strategy lays the foundation for the sector's growth and success. International pharma will play a key, collaborative role in helping to realise these ambitions, through tech-transfer, talent, and shared expertise.
The KSA accounts for 60% of the pharma market in the Gulf, making it well-placed as the home of a brand-new event for the region – CPHI Middle East.
Set to be the region’s most comprehensive pharma gathering, the exhibition will bring together regional drug manufacturers and global suppliers of raw materials, machinery, packaging solutions, contract services, biopharma, and finished dosage.
Beyond partnering and networking opportunities, CPHI Middle East will offer an extensive content programme, including a dedicated Biologics track, offering attendees the chance to hear from industry thought leaders, to build expertise, and to understand the wealth of future opportunities.
CPHI is coming to Saudi Arabia – a place at the forefront of innovation in pharma, where you can make endless connections. See more about the region's largest gathering of pharmaceutical experts here.
CPHI Middle East will bring together regional drug manufacturers with global suppliers of raw materials, machinery, packaging solutions, contract services, biopharma, and finished dosage. Download the exhibitor brochure here.
Related News
-
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Wegovy® – the weight-loss drug sparking a global race to end obesity
Wegovy®, the weight loss drug from Novo Nordisk has been creating headlines since it’s early testing phases, through it’s approval in June 2021 by the US FDA and January 2022 from the European Medicines Agency, and it continues to do so... -
News US FDA approves three different oncology drugs in 1 week
In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications. -
News What the Novo Holdings and Catalent deal means for pharma outsourcing
On February 5, 2024, Novo Holdings announced their intention to acquire pharma and biotech CDMO Catalent at US$16.5 billion. Read more about what this means for the pharmaceutical industry as a whole, from drugmakers to their partners in manufacturing.... -
News Novo Holdings buys CDMO Catalent in US$16.5 billion deal
Novo Nordisk’s holding and investment parent company will acquire the publicly owned CDMO at the end of 2024, taking it private and selling three of its drug manufacturing facilities to Novo Nordisk.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance